PT-141 Australia

PT-141 Australia. PT-141, also called bremelanotide, is the most heavily developed compound of its type. Its research sits almost entirely on MC4R, and because that receptor is in the brain rather than on peripheral tissue, the reported outcomes are central rather than vascular. That is the distinction from the erectile dysfunction drugs, which work on blood flow. The clinical work reports increased sexual desire and arousal response. It went through full human trials and was approved in the United States as bremelanotide for hypoactive sexual desire disorder in premenopausal women. Secondary strands report lower appetite and food intake, and there is an unrelated body of work on haemorrhagic shock and resuscitation.

How it does it. PT-141 is Melanotan II's closest relative, the same ring shaped copy of α-MSH differing by a single chemical group at one end of the molecule, a free acid where MT-2 has an amide. That one small change shifts which receptor it favours toward MC4R. Because the two molecules are otherwise identical, they are studied side by side as a clean test of how a change at the end of a peptide alters which receptor it prefers.

What the safety literature reports. The trial safety data records transient blood pressure rises, nausea and flushing, and focal skin hyperpigmentation with repeated use.

The vial. Independently HPLC-tested above 99% purity by Janoshik, with the certificate of analysis published on this page and in the lab-reports library, carrying the measured number and a verifiable Janoshik key. Supplied in a 10 mg freeze-dried vial, dispatched from Australia, AUD pricing. Supplied strictly for in-vitro and laboratory research use only. Not for human or animal consumption, not a therapeutic good, not TGA-approved.

PT-141 (CAS 189691-06-3; molecular formula C50H68N14O10, average molecular weight ≈ 1025 g/mol) is a cyclic heptapeptide sharing the His-Phe-Arg-Trp α-MSH message core. Structurally it is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH — the same lactam-bridged scaffold as Melanotan II, differing only at the C-terminus, which is a free carboxylic acid rather than an amide. It is the C-terminal-free-acid analogue of MT-2 (the two molecular formulas differ by exactly the amide-to-acid change).

In receptor and pathway research, PT-141 is characterised as a melanocortin-receptor agonist, described in the melanocortin-pharmacology literature as an agonist at melanocortin receptors including MC3R and MC4R (Molinoff and colleagues, Annals of the New York Academy of Sciences, 2003), with MC4R the principal receptor of research interest. It derives from the cyclic lactam α-melanotropin scaffold reported by Al-Obeidi and colleagues (Journal of Medicinal Chemistry, 1989) and is covered in the melanocortin-receptor pharmacology review of Shadiack and colleagues (Current Topics in Medicinal Chemistry, 2007).

PT-141 is used in research as a melanocortin-receptor reference ligand, distinguished from its MT-2 parent by the free-acid C-terminus. Its value in research is as a defined cyclic α-MSH analogue for melanocortin-receptor-pathway work.

The single amide-to-acid difference at the C-terminus separates PT-141 from Melanotan II while preserving the shared His-Phe-Arg-Trp message core, so the two are frequently compared in melanocortin-receptor research to probe how C-terminal chemistry affects receptor recognition and selectivity. MC4R — the principal receptor of research interest for this compound — is expressed predominantly in the central nervous system, which is why PT-141 is referenced in central-melanocortin-pathway research.

The information provided here is a research-reference summary only. Elite AU Peptides makes no medical, therapeutic, sexual-function, or human-use claim about this product. PT-141 is not supplied as a therapeutic good, is not TGA-approved for supply as a research reagent, and is supplied strictly for in-vitro and laboratory research use only. Researchers should consult the primary peer-reviewed literature for receptor-binding data and protocol-specific reference values.

Reconstitute the lyophilised PT-141 vial with bacteriostatic water for laboratory handling. The peptide is water-soluble; add the diluent slowly down the vial wall and swirl gently rather than shaking. A 10 mg vial reconstituted in 2 mL of bacteriostatic water yields a 5 mg/mL working stock — adjust to your protocol’s target concentration.

Store the lyophilised powder at −20°C, desiccated and protected from light; once reconstituted, store refrigerated at 2–8°C and use within the documented research window, or aliquot and freeze to avoid repeated freeze-thaw cycles. Tamper-evident packaging; the batch label is the canonical reference for the certificate of analysis published in the lab-reports library.

Shop bacteriostatic water · Reconstitution calculator

Australia only. Free shipping over $100. Orders placed before 12pm AEST are dispatched the same business day from Australia.

30-day returns on unused product in original packaging, with prior approval.